Farmigea head of research Marco Sansò: ‘Research and innovation to maintain leadership in a constantly evolving market’

"In 2018 we filed a new patent application, in 2019 we started the PCT process. This year we will submit another application"

The Farmigea head of research Marco Sansò presents the research activity 2018-2023 and the future strategy. “In an increasingly globalized world and in a constantly changing market, we are increasingly convinced to research innovative solutions for ophthalmology. We have been present, for several years, in dozens of countries with our patents and our products, recognized as innovative and competitive.” said Sansò.

Farmigea does research and innovation together with universities and research institutes accredited by the competent authority for preclinical and clinical trials. We add to this our industrial partners, leaders in the production of active ingredients, are a key element in maintaining competitiveness.

We have active research projects in pharmaceutical, medical device (such as products and technology innovations) and nutraceutical. Particular attention is given in the study of the pathology of ocular dryness.

“For years Farmigea has focused its attention on natural products, as demonstrated by its latest patent registered for an association of natural polymers. This patent is the basis of a tear replacement of excellent effectiveness.” said Sansò.

Our attention to natural products refers to the tradition and origins of pharmaceutical industry. We have made this choice since the 1990s: to research and study plant products. We continued in the years 2000 working on natural extracts and is currently considering the study of new products always of plant origin.

“Today Farmigea researches, manufactures and sells products and offers them to other companies worldwide. We also do research and innovation for ophthalmic companies for the development of new products. In 2018 we filed a new patent application, in 2019 we started the PCT process. This year we will submit another application.” said Sansò.

Slider
EYE INSIGHT
Slider